Incorporation of intermediary products of 5-FU anabolism into colorectal cancer

G R GILES, LINDA WOODHOUSE, P J FINAN, AND E M CHISHOLM
From the University Department of Surgery, StJames's University Hospital, Leeds

SUMMARY In 18 patients intermediary anabolic metabolites of 5-FU were measured in normal colonic mucosa and colorectal cancer tissue of intravenous bolus injection or continuous infusion. Higher total concentrations of 5-FU products were found in the cancers when compared with normal colonic tissue. There appeared to be no evidence, however, that some patients had a selectively increased ability to incorporate 5-FU into their tumours. Overall higher concentrations of tumour incorporation of 5-FU were found after bolus injection rather than the infusion method, although this difference is statistically not significant.

5-Fluorouracil (5-FU) appears to be the most active cytotoxic agent against colorectal cancer. Using clinical criteria of objective responses it would seem that about 10-26% of patients with advanced cancer have tumour masses which reduce in size after optimal treatment.1 As the cytotoxic action requires incorporation of the agent into tumour cells, a failure to show a response may imply that in these patients there had been a failure of incorporation of 5-FU into the tumour and its conversion to active metabolites because of some intrinsic intracellular defect, or that insufficient 5-FU was activated because of a failure of drug delivery to the tumour tissue, or both explanations may apply.

The activation of 5-FU is a complex process with two main pathways leading to either reduction of DNA synthesis via inhibition of the enzyme thymidylate synthetase$^2$ or by direct incorporation into RNA.$^4$ $^5$ (Fig. 1). The biochemical injury produced by this drug requires more detailed research but it is also possible to investigate the relative inefficiency of 5-FU by investigating the metabolism of 5-FU into its intermediate metabolites which are essential requirements in order that permanent damage of cancer cells can occur.

In this study we have investigated 5-FU incorporation into human colorectal cancer tissue and have measured the concentrations of fluorouracil (FU), fluorouridine (FUR) and fluorodeoxyuridine (FdUR) in the cancer and excised normal colonic mucosa. Two methods of 5-FU administration, bolus injection and continuous intravenous infusion, are compared in terms of the levels of metabolites achieved. In addition two enzymes concerned in the incorporation of 5-FU into the RNA pathway were also assayed.

Methods

PATIENTS

Eighteen patients with colorectal cancer gave informed consent to receiving a single preoperative dose of 5-FU before excision of their cancer. The study had been approved by the local hospital ethical committee.

Of the 18 patients who were investigated 14 were

Address for correspondence: Professor G R Giles, Department of Surgery, St James's University Hospital, Leeds LS9 7TF.

Received for publication 28 May 1985
men and four women. The mean age of the group was 68.2±9.1 years. Six patients had rectal cancer, eight had left sided colonic cancer and the re- 
mainder had right sided colonic cancer. Patients were prepared for colonic surgery by bowel preparation and blood transfusion where necessary 48 
hours before operation. They were randomised to receive 5-FU at a dose of 15 mg/kg either by continuous infusion over 24 hours or by rapid 
intravenous bolus injection over five minutes. 

At the time of surgery samples of both normal and 
malignant colonic epithelium were taken from the 
freshly excised specimens, snap frozen in liquid 
nitrogen and stored at −70°C. Tissue extracts were 
obtained by homogenising the specimens in an equal 
volume of ice cold 10 mmol tris/HCl buffer (pH 7.5), 
containing 10 mmol mercaptoethanol, centrifuging 
at 100 000 g for 30 minutes at 4°C and collecting the 
supernatant to store at −70°C. All reagents except 
where otherwise stated were of analytical grade, 
from BDH Chemicals Ltd (Poole).

ENZYME STUDIES 
The assay of phosphoribosyl transferase (PRT) (EC 
2.4.2.9) was adapted from the radio-isotopic method 
described by Reyes. Sixty microlitres of extract (10 
mmol tris/HCl pH 7-5) was incubated at 37°C for 30 
minutes with 20 μl of 6-0 mmol [6-3H] 5-FU 
(Amersham), 20 μl of 400 mmol tris (HCl) (pH 9-8) 
and 40 μl of 15-0 mmol 5-phosphoribosyl-1- 
pyrophosphate in 15 mmol MgCl₂. Twenty micro-
litre aliquots were taken at 0, 10, 20, and 30 minutes 
and mixed with 500 μl 750 mmol ammonium acetate 
(pH 9-0). The amount of [6-3H] FUMP formed was 
measured by applying the mixture to the borone 
affinity gel prepared as described by Uziel et al. 
The gel was eluted with 250 mmol ammonium acetate 
(pH 8-8) to remove unconverted [6-3H] 5-FU and 
then with 100 mmol formic acid to remove the 
[6-3H] FUMP. The latter was counted using a 
Phillips PW 4540 liquid scintillation analyser and the 
specific activity of the PRT expressed as nmol [6-3H] 
5 FUMP produced/h/gram of protein. The protein 
content of the supernatant was determined using the 
Biuret method. 

The assay of uridine kinase (UK) – (EC 2.7.1.48) 
was based on the radio-isotopic method described by 
Ahmed et al. Forty microlitres of extract in 10 
mmol tris HCl, pH 7-5 (600-900 μg protein) was 
incubated for 40 minutes at 37°C pIC with 40 μl of 50 
mmol [5,6-3H] uridine (Amersham), 40 μl of 69-5 
mmol AATP, 40 μl of 62-4 mmol MgCl₂ and 40 μl of 
mol tris/HCl (pH 7-5) containing 50 mmol B-
mercaptopoethanol. Twenty microlitre aliquots were 
taken at 2, 10, 20, 30, and 40 minutes and spotted on 
DE-81 discs (Whatman Biochemical Ltd). Uncon-
verted [5,6-3H] uridine was eluted from the discs 
with a continuous stream of water. [5,6-3H] uridine 
monophosphate (UMP) was eluted from the disc in 
1 ml of 0-1 mol HCl 0-5 mol NaCl into scintillation 
rolls and counted in a liquid scintillation analyser 
(Phillips PW 4540). The specific activity of UK was 
expressed as nmols of [5-6-3H] UMP/h/g of protein 
in extract. 

FLUORINATED COMPOUNDS 
One hundred milligrams of frozen tissue was 
homogenised in 2 ml of ice cold 2 mol Na F and 200 
μl of ice cold 10 mol acetic acid was immediately 
added to precipitate the proteins. The acidic 
homogenate was frozen and thawed three times and 
then centrifuged at 500 g at 4°C for 20 minutes. The 
clear supernatant was retained and the pellet 
was washed twice with 1 ml of 10 mol acetic acid, 
with 20 minutes of mixing at 4°C before 
washes. The three supernatants were pooled, freeze-dried and stored at 
−20°C until required. 

The chromatographic analysis was done using an 
LDC modular system consisting of a chromatography 
control module (CCM), two Varian III pumps, a variable wavelength UV detector, a 
Magnus Autosampler with Rheodyne valve and 50 
μl loop and a Houston Omnipraphic Printer Plotter. 

The 250 mm × 4.5 mm ID Spherisorb ODS 5 μm 
column was protected by a dry packed 50 mm × 4.5 
mm precolumn containing Whatman CO:PELL ODS. 

A gradient elution using a low concentration buffer 0-02 mol KH₂PO₄ (pH 5-6) and high 
concentration buffer 60/40 vol/vol methanol/water. The 
gradient was introduced at 0-69%/min of high 
concentration buffer, at a flow rate of 1 ml/min and 
a run time of 35 minutes. The compounds were 
quantified at a wavelength of 254 nm and an AUFs 
of 0-01. 

The retention times for FU, FUR and FdUR were 
7.56±0.06 min, 13.49±0.11 min and 16.62±0.11 
min with standards run after every eighth sample. 
The results are expressed as ng/ml of supernatant. 
All statistical analyses were conducted as Mann 
Whitney U tests. 

Results 
Table 1 summarises the group data concerning 
concentrations of fluouracil, fluorouridine, and 
fluorodeoxyuridine in normal colonic mucosa and 
colorectal cancer tissue. The mean concentrations 
of FU detected in the cancer tissue were 20.4±13.1 and 
9.5±5.5 ng/ml after bolus and infusion respectively 
(p<0.05). After bolus injection this was significantly
Table 1  Mean concentrations of intermediary metabolites

<table>
<thead>
<tr>
<th></th>
<th>TFP</th>
<th>FU</th>
<th>FUR</th>
<th>FdUR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal mucosa</td>
<td>193±9.5</td>
<td>8.3±6.4</td>
<td>9.3±8.7</td>
</tr>
<tr>
<td></td>
<td>Tumour</td>
<td>38.7±20.6</td>
<td>20.4±13.1</td>
<td>17.0±11.2</td>
</tr>
<tr>
<td></td>
<td>Bolus</td>
<td>p&lt;0.025</td>
<td>p=0.025</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>Normal mucosa</td>
<td>11.9±6.23</td>
<td>5.3±2.7</td>
<td>3.9±4.1</td>
<td>2.8±1.7</td>
</tr>
<tr>
<td></td>
<td>Tumour</td>
<td>23.6±9.5</td>
<td>9.5±5.5</td>
<td>12.2±9.0</td>
</tr>
<tr>
<td></td>
<td>Infusion</td>
<td>p&lt;0.01</td>
<td>ns</td>
<td>p&lt;0.02</td>
</tr>
</tbody>
</table>

Mann-Whitney U test.
TFP=total fluorinated pyrimidines; FU=fluorouracil; FUR=fluorouridine; FdUR=fluorodeoxyuridine.

higher than normal colonic mucosa (p<0.05 >0.01). Similarly the FUR concentrations in tumour tissue were 17.0±11.2 and 12.2±9.0 ng/ml after bolus and infusion. Again these concentrations were higher than normal colonic mucosa (p<0.05 >0.01). The concentrations of FdUR after both bolus and infusion, however, were similar in both normal mucosa and tumour tissue.

In Figures 2–4 the individual values of these metabolites are shown in normal colonic mucosa and in neoplastic tissues. There appear to be two specimens of normal mucosa in which concentrations of FU are distinctly higher than other values, five have higher concentrations of FUR and four have distinctly higher concentrations of FdUR. Four specimens of neoplastic tissue have higher concentrations of FU, four exceptionally high concentrations of FUR and one high value of FdUR. These values appear to have occurred randomly, however, and no specimen showed consistently high concentrations of all three compounds. Thus there did not appear to be a subset of patients who were able to activate 5-FU more successfully than others and we cannot account for individual tumour susceptibility to 5-FU by these studies.

In Table 2 the data have been arranged differently
so that comparisons between the concentrations achieved by bolus injection or continuous infusion are more easily seen. Significantly higher concentrations of FU after bolus injection was found in normal mucosa, compared with continuous infusion. Similarly the concentrations of FU in tumour tissues were higher after bolus injection and just reached statistical significance at the 5% level. The concentrations of FdUR were not significantly different after either method of treatment.

**ACTIVATING ENZYME CONCENTRATIONS**

The concentrations of activating enzymes were similar in the groups of patients receiving either infusion or bolus of 5-FU and are not considered separately. The mean concentration of phosphoribosyl transferase in normal colonic mucosa was 11.14±5.03 nmol/h/g and 20.7±8.64 in tumour tissue. The difference between the two tissues was significantly different (p<0.01).

The mean uridine kinase concentration in normal colonic mucosa was 2.04±1.31 nmol/h/g compared with 3.73±2.0 in tumour tissue (p>0.05). There was no significant correlation of the total fluorinated pyrimidines in tumour tissue and the concentrations of uridine kinase (r=0.44) or the concentrations of phosphoribosyl transferase (r=0.12) nor between enzyme levels and intermediate metabolites. Similarly the total fluorinated compounds or other fractions in normal colonic mucosa could not be correlated to uridine kinase (r=0.11) or phosphoribosyl transferase levels (r=0.13).

**Discussion**

In order to produce cell damage, 5-FU must be converted within the cell to either fluorodeoxyuridine monophosphate (FdUMP), which acts to inhibit thymidilate synthetase and DNA synthesis, or fluorouridine triphosphate (FUTP), which is incorporated into and interferes with, the function of RNA. The formation of both these nucleotides is preceded by the conversion of 5-FU to fluorouridine monophosphate (FUMP), which can occur by two pathways: the sequential action of the enzymes uridine phosphorylase and uridine kinase, or by a direct conversion to FUMP by the action of phosphoribosyl transferase (Fig. 1). An alternative route may involve the action of thymidine phosphorylase and thymidine kinase with the formation of an intermediate metabolite of fluorodeoxyuridine (FdUR). The formation of FdUMP and FUTP may be reflected in the levels of 5-FU, FdUR and FUR, which can be found in the tissue under investigation. The association of these compounds with the pharmacokinetics of 5-FU, as detected in plasma concentrations, remains to be established.

The relatively poor clinical response to 5-FU therapy and the similarity of clinical response rate over a fairly wide range of dose regimens argue in favour of the idea that there may be some selectivity in the metabolic incorporation of 5-FU, which is due to differences in the concentrations of activating enzymes.
to either pharmokinetic differences or to the individual's ability to incorporate 5-FU at a cellular level. Our group has previously shown that the concentrations of uridine and thymidine phosphorylase in colorectal tumours are higher than those found in normal colonic mucosa so that the initial conversion of 5-FU to 5-fluorouridine or 5-fluorodeoxyuridine should not be inhibited by enzyme lack. Similarly this study has shown that the concentrations of uridine kinase which act on the conversion of fluorouridine to fluorouridine monophosphate (FUMP) and phosphoribosyl transferase, which converts uracil directly to FUMP, are significantly raised in colonic cancer above the normal levels. These raised levels are probably an indication of increased cell turnover in the tumour tissue and suggest that the early enzymatic conversion of intracellular 5-FU should present no problem, as almost all tumours show a raised enzyme concentration. This factor does not appear to have discriminatory value to detect tumours unable to incorporate 5-FU which is contrary to previous reports. An analysis of specific activities of these enzymes, however, may ultimately identify responding patients as shown by Ardalan et al in a study of diphosphate kinases in breast cancer patients.

It has been shown that the ability of cell free supernatants of murine tumours to produce phosphorylated products of 5-FU can be correlated with in vitro sensitivity of the tumours to 5-FU. Furthermore tumours resistant to 5-FU in vivo showed distinctly different patterns of 5-FU phosphorylase in vitro, particularly in terms of concentration differences of diphosphate and triphosphate peaks. The same group of investigators have also shown that in patients with advanced breast cancer there are significant differences in the in vitro conversion of 5-FU to FUR and FdUMP in responding patients when compared with non-responding patients. This study has shown that 5-FU incorporation into human colorectal tumours can be detected as 5-fluorouracil, 5-fluorouridine or 5-deoxyfluorouridine. Colorectal cancer tissue appears to contain significantly more fluorinated products than normal colonic mucosa whether the drug is given by bolus or infusion regimen. This difference is, however, not expressed by changes in the measured concentrations of FdUR. It is also apparent that tumours from some patients apparently incorporate more 5-FU than others and this may ultimately identify those patients in whom it might be expected that a 5-FU cytotoxic effect could beneficially occur, though this is speculative at this time and requires formal clinical trial.

If as expected tumour sensitivity to 5-FU can be related to incorporation into RNA and DNA metabolism, then in vitro culture of explants with labelled 5-FU may also give some indication of drug effect. This method of sensitivity testing, however, does not take account of the pharmokinetics of the agent, which may be relevant to the clinical response. In this study it has proved possible to compare the tumour incorporation of 5-FU after bolus or continuous infusion. The total fluorinated products, fluorouracil, and fluorouridine were higher in both normal colonic mucosa and tumour tissue after bolus injection than after a continuous 24 hour infusion. This did not apply to FdU concentrations, however, which were equivalent. This is a surprising result as it might be expected that as RNA synthesis continues throughout the cell cycle – that is, not confined to the time of DNA replication that continuous infusion of 5-FU would give high concentrations of RNA incorporation – that is, raised concentrations of FUR. It is difficult to be certain that the temporal relationship of the drug delivery was strictly comparable between the two regimens but the results are nevertheless interesting. It illustrates the need to take account of drug handling by the patient, however, as lower concentrations of 5-FU in bone marrow have been shown after continuous infusion when compared with other methods of administration.

If this approach of in vivo drug testing proves to correlate with clinical effect, it should also be possible to monitor the modulation of 5-FU incorporation – for example, as in sequential methotrexate-5-FU regimens or after priming of the tumour with thymidine and to optimise cytotoxic action. A comparison of tumour tissue and normal mucosa removed in the same operation may well predict drug toxicity and permit the development of new methods to protect the normal tissues.

References

Incorporation of intermediary products of 5-FU anabolism into colorectal cancer


10 Finan PJ, Koklitis PA, Chisholm EM, Giles GR. Comparative levels of tissue enzymes concerned in the early metabolism of 5-Fluorouracil in normal and malignant human colorectal tissue. Br J Cancer 1984; 50: 711-5.


